Aardvark Therapeutics Analyst Price Targets - Benzinga

Aardvark Therapeutics Inc

AARDNASDAQ

Trade with Public

Trade with Public

$6.37

-0.38-5.63%

Últ. Act.: Aug 20, 10:47 AM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

Aardvark Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aardvark Therapeutics (AARD).

Price Target Range — 7 Quarters

Analyst Consensus — 11 Analysts

6Buy

4Hold

1Sell

Consensus RatingBuy# Analysts11Avg. Consensus PT$17Upside to Avg. PT+173.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 20, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Neutral	$6
May 15, 2026	B. Riley Securities	William Woods	PT Cut	Buy	$8→$7
May 15, 2026	BTIG	Jeet Mukherjee	Downgrade	Buy→Neutral	—
May 15, 2026	Morgan Stanley	Michael Ulz	Downgrade	Equal-Weight→Underweight	$7→$3
Mar 24, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$9
Mar 2, 2026	Oppenheimer	Leland Gershell	PT Cut	Outperform	$35→$21
Mar 2, 2026	BTIG	Jeet Mukherjee	PT Cut	Buy	$26→$9
Mar 2, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Downgrade	Buy→Neutral	—
Mar 2, 2026	Morgan Stanley	Michael Ulz	Downgrade	Overweight→Equal-Weight	$29→$7
Mar 2, 2026	Stifel	James Condulis	Downgrade	Buy→Hold	$24→$6
Mar 2, 2026	RBC Capital	Brian Abrahams	Downgrade	Outperform→Sector Perform	$18→$6
Feb 10, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$26
Feb 9, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$40
Dec 23, 2025	Oppenheimer	Leland Gershell	Initiate	Outperform	$35
Dec 12, 2025	William Blair	Andy Hsieh	Initiate	Outperform	—
Nov 14, 2025	RBC Capital	Brian Abrahams	PT Cut	Outperform	$19→$18
Nov 7, 2025	BTIG	Jeet Mukherjee	Initiate	Buy	$26
Oct 1, 2025	Jones Trading	Catherine Novack	Initiate	Buy	$33
Sep 29, 2025	Stifel	James Condulis	Initiate	Buy	$24
Sep 23, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$40

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and announces $6 price target.

Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7

B. Riley Securities analyst William Woods maintains Aardvark Therapeutics (NASDAQ:AARD) with a Buy and lowers the price target from $8 to $7.

Benzinga Newsdesk

This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Top Wall Street analysts changed outlook on top names. DA Davidson initiated coverage on EBC & UNTY with Buy ratings. See other analyst views.

Avi Kapoor

PRO
BTIG Downgrades Aardvark Therapeutics to Neutral

BTIG analyst Jeet Mukherjee downgrades Aardvark Therapeutics (NASDAQ:AARD) from Buy to Neutral.

Benzinga Newsdesk

FDA Halts Aardvark Therapeutics Rare Disease Study

FDA places full clinical hold on Aardvark's ARD-101 studies as the company reviews Phase 3 safety and efficacy data.

Vandana Singh

This BWX Technologies Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday

Top Wall Street analysts upgraded RXO, BWXT, and Timken stocks with higher price targets. See other analysts' views on these stocks.

Avi Kapoor